All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cassuto, Ophélie, Dufies, Maeva, Jacquel, Arnaud, Robert, Guillaume, Ginet, Clémence, Dubois, Alix, Hamouda, Amine, Puissant, Alexandre, Luciano, Fredéric, Karsenti, Jean-Michel, Legros, Laurence, Cassuto, Jill Patrice, Lenain, Pascal, Auberger, Patrick
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2012
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3681494/
https://ncbi.nlm.nih.gov/pubmed/23238683
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars